Percutaneous device occlusion of iatrogenic heart perforation seems to be a safe and efficient method to treat iatrogenic heart perforation. In order to perform this elegant method, it is however imperative not to prematurely withdraw the perforating catheter to maintain access to the hole for closure.

Percutaneous closure of ASD ostium secundum type defects with the ATRIASEPT is safe and effective with high success rate and excellent mid-term outcome.

Ethanol infusion has been used for the treatment of ventricular arrhythmia. We describe a case of ethanol infusion through the coronary sinus venous network to treat refractory epicardial premature ventricular complexes. The premature ventricular complexes were initially successfully suppressed but recurred after resolution of the myocardial edema. ( Level of Difficulty: Intermediate. )

In a large cohort of unselected adult patients, uNGAL measured four to six hours after PCP was ineffective to predict the risk of CI-AKI and did not correlate with the volume of CM used during the procedure.

Background: There is only limited and conflicting information about the impact of pre-operative chronic kidney disease (CKD) on outcome after transcatheter aortic valve implantation (TAVI). We sought to evaluate the impact of pre-operative CKD on clinical outcome after TAVI, with either balloon-or self-expandable prosthesis, using transfemoral or alternative access, in high risk patients with severe aortic stenosis. Methods: We retrospectively analyzed pooled data from 4 centers' prospective TAVI databases (942 patients). VARC endpoint definitions were used. Patients were subdivided into 4 categories of eGFR to examine the effect of: no (Ͼ 90 ml/min/1.73 m 2 ), mild (61 to 90 ml/min/1.73 m 2 ), moderate (31 -60 ml/min/1.73 m 2 ) and severe (Յ 30 ml/min/1.73 m 2 ) CKD. To assess the effect of renal function on short-and long-term outcome, univariable and multivariable logistic regressions were used; no-CKD category was the reference category. Results: No CKD was found in 109 patients (11.6%); 330 (35 %) had mild, 400 (42.4 %) moderate and 103 (11%) severe CKD. Baseline and procedural characteristics were similar among all groups except for the Logistic EuroSCORE, incidence of severe left ventricular dysfunction, anemia, and a transapical approach, which was higher when the CKD was more severe. Major stroke (severe CKD: 4.9 %, moderate: 2.8 %, mild: 1.2 %, no: 1.8 %, pϭ0.05), life-threatening bleeding (severe CKD: 24.3%, moderate 14.8 %, mild: 11.2 %, no: 8.3 %, pϽ0.001), all-cause 30-day mortality (severe CKD 9.7%, moderate 8.5%, mild 6.7%, no 1.7%, pϭ0.02) and one-year mortality differed significantly across CKD groups. By multivariate analysis, severe CKD (HR 4.21, 95 % CI 1.67-10.66) was an independant predictor of one-year mortality. Conclusions: Patients with CKD who undergo TAVI have a higher risk profile and a worse 30-day and one-year outcome. Severe CKD at baseline is an independent predictor of 1-year mortality after TAVI.